Blue Jet Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare's board approved audited FY25 results with an unmodified (clean) opinion from statutory auditors KKC & Associates LLP. Revenue from operations jumped to ₹1,029.99 crore from ₹711.60 crore last year (~45% growth), while net profit surged to ₹305.20 crore from ₹163.75 crore (~86% growth). EPS rose sharply to ₹17.59 from ₹9.44. The board recommended a final dividend of ₹1.20 per share (60%) subject to shareholder approval. The company also announced plans to raise up to ₹1,500 crore through equity shares or convertible securities via QIP, preferential issue, or private placement, and proposed acquiring a 30,366 sq. meter industrial plot in Dahej, Gujarat for ~₹11.12 crore for manufacturing expansion. A senior management personnel was also appointed. Note: FY25 results were partly aided by a change in depreciation method (WDV to SLM), which boosted pre-tax profit by ₹14.44 crore.
Strong topline and bottomline growth is positive for shareholders, and the ₹1.20 dividend signals healthy cash returns. However, the proposed ₹1,500 crore equity fundraising could lead to share dilution depending on the route and pricing, which may pressure the stock in the short term. The Dahej land acquisition points to future capacity expansion.